3-氟-1-甲基哌啶-4-酮 | 845256-59-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氟-1-甲基哌啶-4-酮
• 中文别名: 3-氟-4-氧代哌啶-1-甲酸苄酯
• 英文名称: benzyl 3-fluoro-4-oxopiperidine-1-carboxylate
• 英文别名: 3-fluoro-4-oxopiperidine-1-carboxylic acid benzyl ester；phenylmethyl 3-fluoro-4-oxo-1-piperidine carboxylate；rac-benzyl 3-fluoro-4-oxopiperidine-1-carboxylate；N-benzyloxy carbonyl-3-(±)-fluoro-4-oxo-piperidine
• CAS: 845256-59-9
• 化学式: C₁₃H₁₄FNO₃
• 分子量: 251.257
• InChiKey: JECCYYOJLNSUHX-UHFFFAOYSA-N

物化性质

• 沸点：
  382.2±42.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8°C，密封保存，避免潮湿。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Benzyl 3-fluoro-4-oxopiperidine-1-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Benzyl 3-fluoro-4-oxopiperidine-1-carboxylate
CAS number: 845256-59-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H14FNO3
Molecular weight: 251.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氟-1-甲基哌啶-4-酮 在 palladium 10% on activated carbon 盐酸 、 4-二甲氨基吡啶 、 1,4-环己二烯 、 三乙酰氧基硼氢化钠 、 sodium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 醋酸异丙酯 、 水 、 1,2-二氯乙烷 为溶剂， 反应 21.75h， 生成 (2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoropiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide
  参考文献：
  名称：

  WO2006/101780

  摘要：

  公开号：
• 作为产物：
  描述：

  Benzyl 3-fluoro-4,4-dimethoxypiperidine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以93%的产率得到3-氟-1-甲基哌啶-4-酮
  参考文献：
  名称：

  使用Selectfluor™的酸催化对酮，缩酮和酰胺的直接亲电子氟化的影响

  摘要：

  使用亲电子氟化试剂Selectfluor™（F-TEDA-BF 4）。对于酮和缩酮的反应，发现使用硫酸（0.1当量）作为添加剂有助于反应，从而导致更快的产物形成。该行为类似于酸催化作用对酮的溴化的已知作用。反应通常具有很高的选择性，导致形成单氟化产物，并且可以使用基于N-保护的哌啶酮的底物以高达85 mmol的反应规模完成反应。在MeOH存在下的反应取决于底物导致相应的氟代酮或氟代缩酮的形成。以这种方式形成氟代缩酮以及环状酰胺的氟化是多组分偶联反应的实例。

  DOI：

  10.1016/j.tetlet.2012.03.074
• 作为试剂：
  描述：

  4-(三甲基硅基氧基)-5,6-二氢吡啶-1(2H)-甲酸苄酯 、 1-Chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) 在 乙酸乙酯 、 水 、 Sodium sulfate-III 、 3-氟-1-甲基哌啶-4-酮 作用下， 以 乙腈 、 乙醇 为溶剂， 反应 16.0h， 以to give 3-fluoro-4-oxo-piperidine-1-carboxylic acid benzyl ester (3.1 g) To a stirred solution of 3-fluoro-4-oxo-piperidine-1-carboxylic acid benzyl ester (500 mg, 2 mmol) in ethanol (6 mL)的产率得到3-氟-1-甲基哌啶-4-酮
  参考文献：
  名称：

  Phenyl-heteroaryl derivatives and methods of use thereof

  摘要：

  本发明提供了公式（I）的苯基-杂环芳基衍生物及其药学上可接受的盐。这些化合物可用于治疗RAGE介导的疾病，如阿尔茨海默病。本发明还涉及制备公式（I）的化合物及其药学上可接受的盐的方法，包括这些化合物的制药组合物，以及在治疗RAGE介导的疾病中使用这些化合物和/或制药组合物。

  公开号：

  US08741900B2

文献信息

• [EN] N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF<br/>[FR] N-CYCLOPROPYL-N-PIPÉRIDINYL-AMIDES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014019967A1

  公开（公告）日：2014-02-06

  The present invention relates to compounds of general formula (I), wherein R1, LP, HetAr1, (Het)Ar2 and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式（I）的化合物，其中R1、LP、HetAr1、（Het）Ar2和n如申请中所定义，具有有价值的药理特性，特别是结合GPR119受体并调节其活性。
• 6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
  申请人：BAO JIANMING

  公开号：US20170183342A1

  公开（公告）日：2017-06-29

  The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及6,7-二氢-5H-吡咯[3,4-b]吡啶-5-酮化合物，这些化合物是M4毒蕈碱乙酰胆碱受体的变构调节剂。本发明还涉及在本申请中描述的化合物在潜在治疗或预防神经和精神障碍和疾病中的应用，其中涉及M4毒蕈碱乙酰胆碱受体。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及M4毒蕈碱乙酰胆碱受体的疾病的应用。
• N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF
  申请人：NOSSE Bernd

  公开号：US20140045823A1

  公开（公告）日：2014-02-13

  The present invention relates to compounds of general formula I, wherein R 1 , L P , HetAr 1 , (Het)Ar 2 and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式I的化合物， 其中R 1 ，LP，HetAr 1 ，（Het）Ar 2 和n如申请中所定义，具有有价值的药理特性，特别是结合GPR119受体并调节其活性。
• [EN] AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS<br/>[FR] COMPOSÉS AMINOPYRIMIDINES EN TANT QU'INHIBITEURS DE MUTANTS D'EGFR CONTENANT T790M
  申请人：GENENTECH INC

  公开号：WO2014081718A1

  公开（公告）日：2014-05-30

  This invention relates to novel compounds of formula (I) which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer. (Formula I)

  这项发明涉及公式（I）的新化合物，这些化合物是T790M含有EGFR突变体的抑制剂，涉及含有它们的药物组合物，它们的制备方法，以及它们在预防或治疗癌症中的应用。
• [EN] AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS<br/>[FR] COMPOSÉS D'AZAINDAZOLE EN TANT QU'INHIBITEURS DE LA T790M CONTENANT DES MUTANTS DE L'EGFR
  申请人：GENENTECH INC

  公开号：WO2014210354A1

  公开（公告）日：2014-12-31

  This invention relates to novel compounds of formula (I), which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.

  这项发明涉及公式（I）的新化合物，这些化合物是T790M含有EGFR突变体的抑制剂，涉及含有它们的药物组合物，它们的制备过程，以及它们在预防或治疗癌症中的应用。